Emestedastat for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Nov 2023: Trial registered, NCT06125951
  2. 12 Apr 2024: Trial started, NCT06125951

The trials

NCT06125951: Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

State
Under way
Phase
Phase 2 and Phase 3
People
247 taking part
Started
12 Apr 2024
Primary completion
22 Sep 2026
Arms
10 mg Xanamem, Open label phase
Results
None posted
  1. 9 Nov 2023: Trial registered
  2. 12 Apr 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Xanamem.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.